Inclusion Criteria:
* Individuals aged 18 years and older at time of consent.
* Meets local candidacy criteria for cochlear implantation in the ear to be implanted.
* Failure to satisfactorily treat tinnitus with conventional treatments including Tinnitus Retraining Therapy (TRT) for at least six (6) months as determined by the investigator.
* Moderate to severe tinnitus handicap as determined by \>38 THI score (Grade 3 / Moderate or greater).
* Duration of moderate to severe tinnitus \< 3 years, as determined by the investigator.
* Willing to undergo unilateral cochlear implantation.
* Candidate is a fluent speaker in the language used to assess speech perception performance as determined by the investigator (i.e. Spanish).
* Direct access to a compatible Smart Phone.
* Willing and able to provide written informed consent.
Exclusion Criteria:
* Prior cochlear implantation, in either ear, or medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted.
Participants who meet any of the exclusion criteria described below will not be eligible for this clinical investigation.
* Prior cochlear implantation, in either ear, or medical plan for cochlear implantation during the clinical investigation, contralateral to the ear to be implanted.
* Tinnitus of central origin, pulsatile tinnitus related to blood flow, paroxysmal tinnitus, somatosensory tinnitus, tinnitus related to vertigo or headache, or post-traumatic tinnitus, as determined by the investigator.
* Intra-axial (within-the-brain) lesions or deafness due to lesions of the acoustic nerve affecting the ear to be implanted.
* Middle ear infection (including acute otitis media, chronic otitis media, suppurative otitis media, or serous drainage) in the ear to be implanted either at the time of surgery or within 3 months prior to enrolment.
* Presence of a tympanic membrane perforation or a history of otologic surgery within 3 months prior to enrolment, in the ear to be implanted.
* Previously reported diagnosis of auditory neuropathy, in the ear to be implanted.
* Cochlear ossification, cochlear malformation or any other cochlear anomaly, such as common cavity, that might prevent complete insertion of the electrode array, in the ear to be implanted.
* Current cerebrospinal fluid (CSF) shunts or drains, existing perilymph fistula, skull fracture or CSF leaks.
* Severe, or poorer, bilateral sensorineural hearing loss prior to 5 years of age, as reported by the participant.
* Severe, or poorer, sensorineural hearing loss for more than 15 years, as reported by the participant, in the ear to be implanted.
* Medical or psychological conditions that contraindicate general anaesthesia, surgery, or participation in the clinical investigation as determined by the investigator.
* Preexisting skin condition that could jeopardize wound healing, as determined by the investigator e.g., psoriasis, dermatitis, use of corticosteroids, uncontrolled diabetes.
* Unrealistic expectations on the part of the participant, regarding the possible benefits, risks, and limitations inherent to the surgical procedure(s) and prosthetic devices, as determined by the Investigator.
* Additional disabilities that may affect the participant's participation or safety during the clinical investigation.
* Pregnant women.
* Investigator site personnel directly affiliated with this study and/or their immediate families. Immediate family is defined as spouse, parent, child or sibling.
* Cochlear employees or employees of Contract Research Organisations or contractors engaged by Cochlear for the purposes of the investigation.
* Current participation, or participation in another interventional clinical study/trial in the past 30 days, involving an investigational drug or device that is different from the device in this study.
* Unable or unwilling to comply with the requirements of the clinical investigation as determined by the Investigator.
